Boron neutron capture therapy prolongs survival in a patient with a recurrent malignant peripheral nerve sheath tumor

Boron neutron capture therapy prolongs survival in a patient with a recurrent malignant peripheral nerve sheath tumor—A case report

Published:2024-04-14 Issue:7 Volume:71 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Watanabe Yuko¹^ORCID,Chen Yi‐Wei²,Igaki Hiroshi³,Arakawa Ayumu¹,Tao Kayoko¹,Sugiyama Masanaka¹,Nakajima Miho¹,Shirakawa Nami¹^ORCID,Yanagisawa Shunsuke⁴,Miyakita Yasuji⁴,Yoshida Akihiko⁵,Isohashi Kayako⁶^ORCID,Ono Koji⁶,Narita Yoshitaka⁴,Ogawa Chitose¹

Affiliation:

1. Department of Pediatric Oncology National Cancer Center Hospital Chuo‐ku Tokyo Japan

2. Department of Heavy Particles and Radiation Oncology Taipei Veterans General Hospital Taipei Taiwan

3. Department of Radiation Oncology National Cancer Center Hospital Chuo‐ku Tokyo Japan

4. Department of Neurosurgery and Neuro‐Oncology National Cancer Center Hospital Chuo‐ku Tokyo Japan

5. Department of Diagnostic Pathology National Cancer Center Hospital Chuo‐ku Tokyo Japan

6. Kansai BNCT Medical Center Osaka Medical and Pharmaceutical University Takatsuki‐shi Osaka Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.31011

Reference12 articles.

1. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial

2. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

3. Malignant peripheral nerve sheath tumors: Prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location

4. Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis

5. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST